Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma

BACKGROUND: Primary or secondary drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) is a new challenge in the treatment of advanced non-small cell lung cancer (NSCLC). Osimertinib is a third-generation EGFR-TKI, and its efficacy and safety in NSCLC patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Zhiqiang, Wang, Weimin, Gu, Aiqin, Lu, Jianhong, Huang, Aimi, Xiong, Liwen, Han, Baohui, Jiang, Liyan, Shi, Chunlei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481609/
https://www.ncbi.nlm.nih.gov/pubmed/32953518
http://dx.doi.org/10.21037/tlcr-20-685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481609/
https://www.ncbi.nlm.nih.gov/pubmed/32953518
http://dx.doi.org/10.21037/tlcr-20-685

Ejemplares similares